A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Filterlex Medical, Selected to Receive €7M from the European Innovation Council

Equity investment to support advancement of its breakthrough full-body embolic protection device to reduce the risk of stroke and other complications during left-heart procedures.

Filterlex Medical, a cardiovascular medical device startup, announced today that it has been selected to receive €7 Million equity investment from the European Innovation Council Accelerator (EIC). The EIC equity investment will be a part of Filterlex’s next round of financing.

This combined funding will go towards clinical program expansion, regulatory approvals, and commercialization of the CAPTIS® full-body embolic protection system to help transform left-heart procedures.

Following a rigorous screening process under Horizon 2020, Filterlex’s innovative technology was selected as one of only 99 winning companies out of over 1000, from 21 countries to receive EIC funding from a total of €627 Million available. Entrants must meet EIC criteria for excellence, impact, and risk level, and by the time they reach the final selection stage are considered to be world-class high-impact innovations. Filterlex was also one of only 19% of companies run by a female CEO.

The EIC investment commitment follows Filterlex’s recent rapid closing of a US $6 Million series A1 investment round in November 2021. The company is also a past recipient of a €2.1 Million EU Horizon 2019 grant, which was pivotal in financing the CAPTIS first-in-human study.

Founder and CEO, Sigal Eli, said: “We are delighted to be selected to receive EIC funding for the second time. This EU validation will help us to further advance our technology and turn our vision into a reality to make the CAPTIS a best-in-class device for reducing the risk of stroke and other complications during catheter-based structural heart procedures such as TAVR.”

Filterlex is currently enrolling patients in its successfully ongoing CAPTIS first-in-human study in Israel.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy